gemfibrozil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1285 25812-30-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • gemfibrosil
  • gemfibrozil
  • decrelip
  • lopizid
A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.
  • Molecular weight: 250.34
  • Formula: C15H22O3
  • CLOGP: 3.94
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 46.53
  • ALOGS: -3.95
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.02 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 79.89 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 98 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 21, 1981 FDA PFIZER PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhabdomyolysis 206.71 13.66 122 9813 41787 46634340
Drug hypersensitivity 69.28 13.66 157 9778 243668 46432459
Blood triglycerides increased 54.60 13.66 33 9902 11750 46664377
Coronary artery disease 43.00 13.66 44 9891 33708 46642419
Blood creatine phosphokinase increased 42.52 13.66 40 9895 27684 46648443
Myocardial infarction 37.21 13.66 71 9864 97457 46578670
Acute interstitial pneumonitis 36.63 13.66 11 9924 679 46675448
Myopathy 33.91 13.66 22 9913 8859 46667268
Myalgia 28.13 13.66 73 9862 123015 46553112
Cardiac failure congestive 28.10 13.66 61 9874 91689 46584438
Pancreatitis 27.76 13.66 40 9895 43587 46632540
Cerebrovascular accident 26.31 13.66 63 9872 100976 46575151
Pancreatitis acute 25.65 13.66 29 9906 24843 46651284
Hypertriglyceridaemia 23.94 13.66 15 9920 5689 46670438
Drug interaction 23.18 13.66 95 9840 202999 46473128
Lip infection 23.13 13.66 5 9930 80 46676047
Diabetes mellitus 21.01 13.66 38 9897 50027 46626100
Blood glucose increased 19.93 13.66 46 9889 71967 46604160
Bursitis 18.55 13.66 22 9913 19820 46656307
Tendon rupture 17.59 13.66 14 9921 7745 46668382
Off label use 16.64 13.66 35 9900 379806 46296321
Microalbuminuria 16.37 13.66 5 9930 327 46675800
Rheumatoid arthritis 15.46 13.66 17 9918 240198 46435929
Diabetes mellitus inadequate control 14.64 13.66 16 9919 13198 46662929
Blood cholesterol increased 13.87 13.66 28 9907 39985 46636142

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhabdomyolysis 526.11 12.88 344 13904 63236 29874994
Acute kidney injury 106.55 12.88 328 13920 273514 29664716
Blood triglycerides increased 103.76 12.88 71 14177 13946 29924284
Blood creatine phosphokinase increased 102.50 12.88 115 14133 43733 29894497
Myalgia 85.17 12.88 140 14108 76527 29861703
Coronary artery disease 66.60 12.88 99 14149 49613 29888617
Blood cholesterol increased 56.78 12.88 54 14194 16916 29921314
Drug hypersensitivity 52.98 12.88 107 14141 68412 29869818
Myocardial infarction 49.96 12.88 152 14096 125473 29812757
Polymyositis 48.23 12.88 20 14228 1416 29936814
Cardiac failure congestive 41.18 12.88 110 14138 84297 29853933
Pancreatitis 34.36 12.88 62 14186 36428 29901802
Off label use 32.17 12.88 43 14205 249247 29688983
Drug interaction 31 12.88 181 14067 199387 29738843
Myopathy 30.40 12.88 31 14217 10555 29927675
International normalised ratio increased 27.19 12.88 66 14182 47673 29890557
Hyperglycaemia 26.02 12.88 54 14194 35146 29903084
Thunderclap headache 25.03 12.88 6 14242 66 29938164
Death 24.94 12.88 87 14161 357196 29581034
Drug abuse 23.81 12.88 5 14243 82067 29856163
Hypertriglyceridaemia 23.77 12.88 24 14224 8074 29930156
Chromaturia 23.59 12.88 31 14217 13834 29924396
Chronic kidney disease 23.37 12.88 54 14194 37784 29900446
Granulocytopenia 23.11 12.88 21 14227 6205 29932025
Haemodialysis 22.41 12.88 27 14221 11046 29927184
Blood glucose increased 22.14 12.88 72 14176 61458 29876772
Type 2 diabetes mellitus 20.96 12.88 29 14219 13593 29924637
Myositis 20.51 12.88 25 14223 10352 29927878
Drug ineffective 20.45 12.88 88 14160 340299 29597931
Reversible cerebral vasoconstriction syndrome 17.72 12.88 6 14242 241 29937989
Erosive duodenitis 17.67 12.88 10 14238 1403 29936827
Blood glucose decreased 17.46 12.88 26 14222 13027 29925203
Angina unstable 17.16 12.88 25 14223 12285 29925945
Angioedema 16.93 12.88 45 14203 34339 29903891
Lacrimation decreased 16.66 12.88 3 14245 6 29938224
Treatment noncompliance 16.66 12.88 37 14211 25216 29913014
Pyrexia 16.55 12.88 78 14170 294411 29643819
Muscular weakness 16.55 12.88 67 14181 63578 29874652
General physical health deterioration 16.47 12.88 14 14234 99930 29838300
Hyperlipidaemia 16.22 12.88 26 14222 13881 29924349
Pneumonia haemophilus 16.14 12.88 6 14242 317 29937913
Fanconi syndrome 15.57 12.88 10 14238 1765 29936465
Metabolic acidosis 15.47 12.88 46 14202 37415 29900815
Product use in unapproved indication 15.26 12.88 8 14240 73685 29864545
Interstitial lung disease 14.93 12.88 5 14243 60192 29878038
Otitis externa 14.78 12.88 8 14240 1029 29937201
Asthenia 14.55 12.88 165 14083 221125 29717105
Breast neoplasm 14.42 12.88 3 14245 16 29938214
Hyperlactacidaemia 14.26 12.88 11 14237 2595 29935635
Tricuspid valve incompetence 14.24 12.88 19 14229 8604 29929626
Blood creatinine increased 14.21 12.88 83 14165 91292 29846938
Iron deficiency anaemia 13.56 12.88 19 14229 9005 29929225
Coronary artery stenosis 13.49 12.88 19 14229 9051 29929179
Renal tubular necrosis 13.20 12.88 25 14223 15226 29923004
Arteriosclerosis coronary artery 13.17 12.88 21 14227 11155 29927075
Supraventricular tachycardia 13.08 12.88 20 14228 10252 29927978
Paralysis 12.95 12.88 15 14233 5886 29932344

Pharmacologic Action:

SourceCodeDescription
ATC C10AB04 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
Fibrates
FDA CS M0199111 PPAR alpha
FDA MoA N0000175375 Peroxisome Proliferator-activated Receptor alpha Agonists
FDA EPC N0000175596 Peroxisome Proliferator Receptor alpha Agonist
CHEBI has role CHEBI:35679 hypolipidemic agent
MeSH PA D000963 Antimetabolites
MeSH PA D065687 Cytochrome P-450 CYP2C8 Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D000960 Hypolipidemic Agents
MeSH PA D057847 Lipid Regulating Agents
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertriglyceridemia indication 302870006
Primary Prevention of Coronary Heart Disease indication
Hypoalphalipoproteinemia off-label use 190785000
Primary biliary cirrhosis contraindication 31712002 DOID:12236
Disorder of gallbladder contraindication 39621005 DOID:0060262
Acute nephropathy contraindication 58574008
Leukopenia contraindication 84828003 DOID:615
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Calculus in biliary tract contraindication 266474003
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Breastfeeding (mother) contraindication 413712001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.13 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Peroxisome proliferator-activated receptor alpha Nuclear hormone receptor AGONIST EC50 4.23 IUPHAR CHEMBL
Cytochrome P450 2C8 Enzyme Ki 5.74 WOMBAT-PK
Lipoprotein lipase Enzyme WOMBAT-PK
Cytochrome P450 2C9 Enzyme Ki 4.52 WOMBAT-PK
Transthyretin Secreted Kd 7 CHEMBL
Fatty acid-binding protein, liver Unclassified Ki 5.73 CHEMBL

External reference:

IDSource
4018639 VUID
N0000146952 NUI
D00334 KEGG_DRUG
4018639 VANDF
C1567527 UMLSCUI
CHEBI:5296 CHEBI
4TX PDB_CHEM_ID
CHEMBL457 ChEMBL_ID
DB01241 DRUGBANK_ID
D015248 MESH_DESCRIPTOR_UI
3463 PUBCHEM_CID
3439 IUPHAR_LIGAND_ID
3899 INN_ID
Q8X02027X3 UNII
4719 RXNORM
4778 MMSL
523 MMSL
d00245 MMSL
002050 NDDF
35282000 SNOMEDCT_US
387189002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lopid HUMAN PRESCRIPTION DRUG LABEL 1 0071-0737 TABLET, FILM COATED 600 mg ORAL NDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9130 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9707 TABLET, FILM COATED 600 mg ORAL ANDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 0615-8354 TABLET, FILM COATED 600 mg ORAL ANDA 15 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 10544-569 TABLET, FILM COATED 600 mg ORAL ANDA 18 sections
Gemfibrozil Human Prescription Drug Label 1 16571-784 TABLET, FILM COATED 600 mg ORAL ANDA 15 sections
Gemfibrozil Human Prescription Drug Label 1 16714-101 TABLET 600 mg ORAL ANDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 21695-732 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 24658-260 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 31722-128 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 31722-225 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 33261-146 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 42806-260 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 43063-745 TABLET 600 mg ORAL ANDA 11 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 43063-921 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 43353-090 TABLET, FILM COATED 600 mg ORAL ANDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 43353-772 TABLET, FILM COATED 600 mg ORAL ANDA 21 sections
GEMFIBROZIL HUMAN PRESCRIPTION DRUG LABEL 1 43602-452 TABLET 600 mg ORAL ANDA 10 sections
Gemfibrozil Human Prescription Drug Label 1 50090-2450 TABLET, FILM COATED 600 mg ORAL ANDA 15 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 50090-2902 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 50268-350 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 51138-588 TABLET, FILM COATED 600 mg ORAL ANDA 18 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 51655-142 TABLET 600 mg ORAL ANDA 9 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 51655-143 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 53002-1068 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil Human Prescription Drug Label 1 53002-2068 TABLET, FILM COATED 600 mg ORAL ANDA 15 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 53217-251 TABLET 600 mg ORAL ANDA 11 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 53808-0251 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 53808-0368 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections
Gemfibrozil HUMAN PRESCRIPTION DRUG LABEL 1 53808-0673 TABLET, FILM COATED 600 mg ORAL ANDA 17 sections